BioDiem Ltd.

DUBLIN--( BUSINESS WIRE )--The "Global Nasopharyngeal Cancer Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global market for nasopharyngeal cancer is projected to have a considerable CAGR of around 2.6% during the forecast period. Companies Mentioned BioDiem Ltd. Biocon Ltd. Bristol-Myers Squibb Co. Cyclacel Pharmaceuticals, Inc. Eli Lilly and Co. F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc Merck & Co., Inc. Novartis AG ONO Pharmaceutical Co., Ltd Pfizer Inc. Sanofi SA The nasopharynx cancer or nasopharyngeal carcinoma (NPC) results from abnormal growth of cells in the nasopharynx. The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc. The dramatic rise in the prevalence rate of nasopharyngeal cancer owing to the excessive consumption of tobacco and alcohol is the major factor driving the growth of the market. According to the American Institute for Cancer Research estimates, Nasopharyngeal cancer is the 23rd most common cancer worldwide, and it is the 18th most commonly occurring cancer in men and the 22nd most commonly occurring cancer in women. Also, there were 129,000 new cases of nasopharyngeal cancer in 2018 according to the same estimates. Similarly, according to the International Agency for Research on Cancer (IARC) 2018 report, it is estimated that about 50,455 new cases of nasopharyngeal cancer will occur from 2018 to 2040. Thus, the high prevalence rate of nasopharyngeal cancer will increase the demands for effective drugs and therapies that will further lead to market growth. Moreover, the high cost of treatment, low awareness of cancer and an adverse side effect of treatment are the major restraint factors that are hindering the growth of the market. As per the National Center for Biotechnology Information, the cost of treatment of NPC ranges from $15,000 to $18,000. On the other hand, the rapid adoption of technologies in healthcare premises, increasing awareness campaigns for nasopharyngeal cancer (NPC), and adoption of nasopharyngeal cancer diagnosis and treatment are expected to boost the market growth and will create lucrative opportunities during the forecast period. Impact of COVID-19 on Global Nasopharyngeal Cancer Market The global market for nasopharyngeal cancer has experienced a positive impact due to the COVID-19 pandemic. As patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer, due to this the demand for diagnosis and treatments/therapies associated with this cancer were increased. This led to the growth of the market. Segmental Outlook The global nasopharyngeal cancer market is segmented based on cancer type, diagnosis method, and therapy. Based on cancer type, the market is categorized into keratinizing squamous cell carcinoma, non-keratinizing squamous cell carcinoma, undifferentiated carcinomas, and other (adenocarcinoma and adenoid cystic carcinomas). Based on the diagnosis method, the market is bifurcated into initial diagnosis and advanced diagnosis. The Initial diagnosis is further classified into nasendoscopy, panendoscopy, and fine-needle aspiration/needle biopsy. Similarly, the advanced diagnosis is further classified into CT scan, PET scan, MRI scan, and Bone scan. Whereas, based on therapy, the market is divided into chemotherapy, immunotherapy, surgery, targeted therapy, and radiation therapy. The Radiation Therapy Segment is Projected to Hold the Significant Market Share in Nasopharyngeal Cancer Market Based on therapy, the radiation therapy segment is projected to grow at a significant CAGR during the forecast period. Radiation therapy is the most preferred and common therapy among all other therapies for the treatment of nasopharyngeal cancer. in radiation therapy, high-energy x-rays or particles are used to kill cancer cells or slow their rate of growth. Most of the time, radiation therapy is given along with chemotherapy to increase its effects in the treatment of NPC. This procedure is called chemoradiation. There are two types of radiation therapy for NPC are external beam radiation therapy (EBRT), and brachytherapy (internal radiation). Due to the increasing prevalence of nasopharyngeal cancer rates, the increase in the adoption of this therapy has been witnessed. Thus, owing to the above factors the segment is expected to show growth in the near future. Regional Outlook Geographically, the global Nasopharyngeal Cancer market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, North America is the fastest growing region during the forecast period. The factors that drive the growth of the market in the region include, the increasing cases of nasopharyngeal cancer owing to the high consumption of alcohol, tobacco, and cigarette. The development in the healthcare sectors and the adoption of advanced treatments and therapies for nasopharyngeal cancer is also propelling the growth of the market. The Report Covers Market value data analysis of 2020 and forecast to 2027. Annualized market revenues ($ million) for each market segment. Country-wise analysis of major geographical regions. Key companies operating in the global Nasopharyngeal Cancer market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report. Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. Analysis of market entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market. For more information about this report visit https://www.researchandmarkets.com/r/90drgn

Increase in prevalence of seasonal influenza and R&D of new influenza vaccines play a major role in the growth of the influenza vaccine market. Furthermore, increase in government focus on immunization programs is expected to boost the market growth in the coming years. Influenza Vaccine Market contributed $3.96 billion in 2018 and is projected to garner $6.20 billion by 2026, witnessing a CAGR of 5.9% from 2019 to 2026. The report provides a detailed analysis of changing market dynamics, key segments, top winning strategies, competitive landscape, and others. An increase in prevalence of influenza, advancements in technologies regarding vaccine administration, and governments’ focus on immunization activities facilitate the growth of the global influenza vaccine market. However, high costs of vaccine development and strict regulatory scenario restrain the market growth. On the other hand, unexplored potential in the emerging nations and the introduction of vaccines offer various opportunities in the market. Request for Sample Report for More Insights@ On the basis of vaccine type, the quadrivalent segment accounted for around two-thirds of the total market share in 2018 and is expected to continue to lead throughout the forecast period. Moreover, this segment is expected to register the highest CAGR of 6.1% from 2019 to 2026. This is attributed to the cost-effectiveness and efficacy to provide better protection against viral strains. The study also explores the trivalent segment. On the basis of technology, the cell-based segment is expected to grow at the largest CAGR of 6.5% from 2019 to 2026, owing to the elimination of contamination, cell banking facilities, and better protection as compared to traditional vaccines. However, the egg-based segment held the highest share of the global influenza vaccine market, contributing nearly nine-tenths of the total market share in 2018, and is expected to maintain its dominance throughout the forecast period. Based on region, North America contributed the highest market share in 2018, contributing nearly half of the total market, and is estimated to contribute its highest share during the forecast period. However, LAMEA is estimated to register the largest CAGR of 7.5% from 2019 to 2026. This is attributed to better healthcare facilities and rise in pace of economic developments in this region. Leading market players analyzed in the report include AstraZeneca Plc. CSL Limited Biodiem F. Hoffmann-La Roche Ltd. Emergent BioSolutions GlaxoSmithKline Plc. Gamma Vaccines Pvt. Ltd. Novartis AG Merck & Co., Inc. (Merck Sharp & Dohme Corp.) Sanofi Pasteur SA Pfizer, Inc. Sinovac Biotech Ltd. Similar Reports: Skincare Devices Market - Global Opportunity Analysis and Industry Forecast, 2019-2028 Biosimulation Market - Global Opportunity Analysis and Industry Forecast, 2019-2028 About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch (dot) com

Pune, India, March 10, 2021 (GLOBE NEWSWIRE) -- According to the report, Influenza Vaccine Market size is projected to reach USD 7.60 Billion value by 2027, exhibiting a CAGR of 6.9%. The increasing prevalence of chronic disease and the growing efforts in R&D activities by major companies to develop innovative and effective influenza vaccine treatment during the forecast period. Increasing Demand for Flu Vaccine amid COVID-19 to Aid Growth The increasing focus on R&D activities to develop a vaccine to contain the widespread effect of the novel coronavirus is driving the demand for immunization across the globe. The COVID-19 pandemic has brought unprecedented changes in the healthcare industry. An increasing demand for the seasonal influenza vaccine to ensure better protection against the deadly pandemic is anticipated to favor the market growth in the near future. Request a Sample Copy of the Research Report: Influenza, also known as flu, is generally a respiratory illness that occurs due to a viral infection. It is highly contagious and mainly spreads through respiratory droplets. In addition to this, it can pass from one person to another through physical contact and while talking. Owing to their serious implications on health, global healthcare organizations such as the Centers for Disease Control and Prevention (CDC) have recommended certain influenza vaccines such as baloxavir marboxil (Xofluza) to treat the symptoms in patients. The market report includes a detailed assessment of various drivers and restraints, opportunities, and challenges that the market will face during the projected horizon. Additionally, the report provides comprehensive insights into the regional developments of the market, affecting its growth during the forecast period. It includes information sourced from the advice of expert professionals from the industry by our research analysts using several research methodologies. The competitive landscape offers further detailed insights into strategies such as product launches, partnership, merger and acquisition, and collaborations adopted by the companies to maintain market stronghold between 2020 and 2027. Click here to get the short-term and long-term impacts of COVID-19 on this Market. Please visit: Increasing Prevalence of Influenza to Favor Growth According to the World Health Organization (WHO), seasonal influenza has serious implications for health globally. It is estimated that around 1 billion people are affected by it every year. The increasing prevalence of chronic disease is propelling the manufacturers to develop innovative influenza vaccines. The increasing geriatric population globally is further anticipated to favor the global flu vaccine market during the forecast period. The global healthcare organizations have recommended several licensed vaccines that are being adopted largely to prevent chronic diseases that are propelling the companies to invest in developing innovative vaccines globally. This is expected to bode well for the market growth in the forthcoming years. Quick Buy - Influenza Vaccine Market Research Report: Pediatric Segment to Remain at the Forefront; Increasing Adoption of Immunization Strategy to Spur Demand The pediatric segment, based on age group, is expected to showcase an exponential growth. This is attributable to the increasing rate of influenza amongst infants and the younger population that is driving the demand for an efficient influenza vaccine. Presence of Established Companies in North America to Surge Demand Among all the regions, North America is expected to hold the highest position in the global flu vaccine market. This dominance is attributable to the presence of established companies such as Emergent BioSolutions, Inc. that are increasing their focus on developing advanced influenza vaccines for therapeutic purposes in countries such as the U.S. The region stood at USD 2.18 billion in 2019. The market in Asia-Pacific is expected to showcase a significant growth in the forthcoming years. This is ascribable to factors such as the increasing geriatric population and the supportive government initiative to promote influenza vaccine between 2020 and 2027. GlaxoSmithKline plc. (U.K, Europe) Sanofi S.A (France, Europe) AstraZeneca (Cambridge, United Kingdom) Seqirus (Maidenhead, UK) BioDiem (South Melbourne Victoria) Emergent BioSolutions Inc. (Maryland, United States) F. Hoffmann-La Roche Ltd (Basel, Switzerland) Sinovac Biotech Ltd (China) Have Any Query? Ask Our Experts: Global Influenza Vaccine Market Segmentation: By Type: Products Services By Valency: Quadrivalent Trivalent By Age Group Pediatric Adults By Distribution Channel: Hospital & Retail Pharmacies Government Suppliers By Geography North America (U.S. and Canada) Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) Get your Customized Research Report: Have a Look at Related Reports: Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liqui, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2018-2025 Spinal Devices Market Size, Share & Industry Analysis, By Product Type (Fusion Devices (Cervical Devices, Thoracolumbar Devices, and Biologics), Non-Fusion Devices (Vertebral Compression Fracture Devices, Dynamic Stabilization Devices), and Stimulation Devices) By Disease Indication (Degenerative Disc Disease, Traumas & Fractures), By End User (Hospitals & Ambulatory Surgery Centers, Specialty Clinics and Others) and Regional Forecast, 2019-2026 Cardiac Pacemaker Market Size, Share and Industry Analysis By Product (Single Chamber Pacemakers, Dual Chamber Pacemakers, Cardiac Resynchronization Therapy-Pacemakers (CRT-P)), By End User (Hospitals & Clinics, Ambulatory Surgery Centers and Others), and Regional Forecast 2019-2026 Blood Glucose Meter Market Size, Share and Industry Analysis by Product (Continuous Glucose Monitoring Devices, Self-Monitoring Blood Glucose (SMBG) Systems), By Technique (Invasive, Non-Invasive), By Type (Wearable, Non-Wearable), By Distribution Channel (Institutional Sales, Retail Sales, Others), and Regional Forecast 2019-2026 Surgical Robots Market Size Share and Industry Analysis By Application (General Surgery, Gynecology, Urology, Orthopedics, Others), By End User (Hospitals, Ambulatory Surgery Centers, Others) and Regional Forecast, 2019 - 2026 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.